Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.

Bagaria, Sanjay P; Gatalica, Zoran; Maney, Todd; Serie, Daniel; Parasramka, Mansi; Attia, Steven; Krishna, Murli; Joseph, Richard W

Bagaria, Sanjay P; Gatalica, Zoran; Maney, Todd; Serie, Daniel; Parasramka, Mansi; Attia, Steven; Krishna, Murli; Joseph, Richard W.

Afiliação

Bagaria SP; Department of Surgery, Division of General Surgery, Mayo Clinic, Jacksonville, FL, United States.
Gatalica Z; Caris Life Sciences, Phoenix, AZ, United States.
Maney T; Caris Life Sciences, Phoenix, AZ, United States.
Serie D; Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, United States.
Parasramka M; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, United States.
Attia S; Department of Medicine, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, United States.
Krishna M; Department of Pathology, Mayo Clinic, Jacksonville, FL, United States.
Joseph RW; Department of Medicine, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, United States.

Front Oncol ; 8: 71, 2018.

Article em En | MEDLINE | ID: mdl-29623256

Palavras-chave

angiosarcoma; checkpoint pathway; immune microenvironment; programmed death-ligand 1; vascular endothelial growth factor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google